Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SANA

SANA - Sana Biotechnology, Inc. Stock Price, Fair Value and News

$3.37+0.28 (+9.06%)
Market Closed

Price Targets

SANA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SANA Price Action

Last 7 days

7.0%

Last 30 days

-13.1%

Last 90 days

-34.4%

Trailing 12 Months

27.2%

SANA RSI Chart

SANA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SANA Valuation

Market Cap

899.3M

Price/Earnings (Trailing)

-3.68

Price/Free Cashflow

-6.21

SANA Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

SANA Fundamentals

SANA Earnings

Earnings (TTM)

-244.2M

Earnings Growth (Yr)

-19.88%

Earnings Growth (Qtr)

-39.55%

SANA Profitability

Return on Equity

-151.77%

Return on Assets

-58.57%

Free Cashflow Yield

-16.1%

SANA Investor Care

Shares Dilution (1Y)

18.59%

Diluted EPS (TTM)

-0.96

About Sana Biotechnology, Inc.

SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.
 CEO
 WEBSITEsana.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES424

Sana Biotechnology, Inc. Frequently Asked Questions

SANA is the stock ticker symbol of Sana Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Sana Biotechnology, Inc. is 899.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.